Substance / Medication

Perfluorohexyloctane

Overview

Active Ingredient
perfluorohexyloctane
RxNorm CUI
2637547

Indications

® MIEBO(perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Labeler: Bausch & Lomb IncorporatedUpdated: 2025-10-28T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of Perfluorohexyloctane for the Treatment of Patients with Dry Eye Disease: A Meta-Analysis.
Taloni Andrea, Coco Giulia, Pellegrini Marco et al. · Ophthalmic Res · 2025
PMID: 39622217Meta-AnalysisFull text (PMC)
Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent.
Ballesteros-Sánchez Antonio, De-Hita-Cantalejo Concepción, Sánchez-González María Carmen et al. · Ocul Surf · 2023
PMID: 37813152Meta-Analysis
Evaluation of pharmacokinetic properties and anaesthetic effects of propofol in a new perfluorohexyloctane (F6H8) emulsion in rats--A comparative study.
Tsagogiorgas Charalambos, Theisinger Sonja, Heesch Elisabeth et al. · Int J Pharm · 2015
PMID: 25797054Observational
Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery.
Kirchhof Bernd, Wong David, Van Meurs Jan et al. · Am J Ophthalmol · 2002
PMID: 11755844Observational
Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis.
Coco Rosa M, Srivastava Girish K, Andrés-Iglesias Cristina et al. · Br J Ophthalmol · 2019
PMID: 29599249Case Report
Perfluorohexyloctane, pseudohypopyon, and acute glaucoma.
Sampat Venkatadri, Jones Lynval, Harvey Robert et al. · Retina · 2003
PMID: 12652250Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Perfluorohexyloctane (substance)
SNOMED CT
42638511000001106
UMLS CUI
C0766224
RxNorm CUI
2637547
Labeler
Bausch & Lomb Incorporated

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.